Axxcess Wealth Management LLC Acquires 2,032 Shares of Amgen Inc. $AMGN

Axxcess Wealth Management LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 14.4% in the 1st quarter, Holdings Channel.com reports. The firm owned 16,141 shares of the medical research company’s stock after acquiring an additional 2,032 shares during the period. Axxcess Wealth Management LLC’s holdings in Amgen were worth $5,679,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Saxon Interests Inc. lifted its position in Amgen by 4.2% during the first quarter. Saxon Interests Inc. now owns 1,902 shares of the medical research company’s stock worth $669,000 after purchasing an additional 77 shares during the period. Childress Capital Advisors LLC raised its position in shares of Amgen by 6.2% in the 1st quarter. Childress Capital Advisors LLC now owns 3,950 shares of the medical research company’s stock valued at $1,390,000 after buying an additional 232 shares in the last quarter. Marino Stram & Associates LLC lifted its holdings in shares of Amgen by 1.1% during the 1st quarter. Marino Stram & Associates LLC now owns 5,457 shares of the medical research company’s stock worth $1,920,000 after acquiring an additional 58 shares during the period. Aljian Capital Management LLC lifted its holdings in shares of Amgen by 0.6% during the 1st quarter. Aljian Capital Management LLC now owns 5,713 shares of the medical research company’s stock worth $2,010,000 after acquiring an additional 35 shares during the period. Finally, Bank of Stockton boosted its position in shares of Amgen by 75.6% during the 1st quarter. Bank of Stockton now owns 1,431 shares of the medical research company’s stock worth $503,000 after acquiring an additional 616 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received an upgrade to Zacks Rank #2 (Buy), which signals improving earnings expectations and could help sentiment near term.
• Positive Sentiment: Biotech stocks may be getting a boost from a more favorable M&A backdrop, with Jim Cramer calling biotech “the hottest group in the market” and suggesting deal activity could accelerate.
• Positive Sentiment: Several analysts raised or reaffirmed price targets on AMGN, including Truist lifting its target to $340 and Cantor Fitzgerald reaffirming a neutral stance with a $350 target, which still reflects solid long-term value expectations.
• Neutral Sentiment: Commentary on Amgen’s dividend safety suggests investors are still weighing near-term headwinds against the company’s cash generation and payout profile.
• Negative Sentiment: Amgen initiated broad U.S. recalls of Sensipar and Corlanor tied to CGMP deviations and contamination concerns, raising quality-control questions across multiple lots and dosage strengths.
• Negative Sentiment: Ongoing scrutiny around Tavneos and pipeline uncertainty continue to weigh on the shares, as regulators challenge the drug’s approval and investors reassess future growth prospects.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of recent analyst reports. Argus decreased their price objective on shares of Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a research note on Wednesday, May 20th. Guggenheim cut their target price on Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a research note on Monday, May 4th. Truist Financial raised their target price on Amgen from $327.00 to $340.00 and gave the company a “hold” rating in a report on Tuesday. Mizuho lifted their price target on Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a research note on Tuesday, June 16th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $400.00 price target on shares of Amgen in a report on Wednesday, July 1st. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $356.00.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.85% of the stock is currently owned by insiders.

Amgen Stock Performance

NASDAQ AMGN opened at $368.10 on Wednesday. The firm’s fifty day moving average price is $343.26 and its two-hundred day moving average price is $348.66. The stock has a market cap of $198.67 billion, a PE ratio of 25.62, a PEG ratio of 3.61 and a beta of 0.41. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same period in the prior year, the company earned $4.90 EPS. Amgen’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities analysts expect that Amgen Inc. will post 22.39 EPS for the current fiscal year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.